Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes
Robert I. Haddad(Georgetown University), Robert L. Ferris(University of Pittsburgh), Makoto Tahara(National Cancer Center Hospital East), Mark Lynch(Fluidigm (United States)), A.D. Colevas(Stanford University), Jérôme Fayette(Université Claude Bernard Lyon 1), F. P. Worden(University of Michigan), Nabil F. Saba(Emory University), Lisa Licitra(University of Milan), Stefan Kasper(Essen University Hospital), Everett E. Vokes(University of Chicago), L. Li(Bristol-Myers Squibb (United States)), Fernando Concha‐Benavente(UPMC Hillman Cancer Center), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Manish Monga(Institut Gustave Roussy), Maura L. Gillison(The University of Texas MD Anderson Cancer Center), George R. Blumenschein(The University of Texas MD Anderson Cancer Center), James W. Shaw(University of Illinois Chicago), J. Guigay(Centre Antoine Lacassagne)
Cited by 36
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k